Top in ID: Pneumonia antibiotic; second bivalent COVID-19 booster for older adults
Click Here to Manage Email Alerts
An FDA advisory committee voted to recommend the approval of sulbactam-durlobactam for adults with bacterial pneumonia after reviewing data from a two-part phase 3 trial that compared its safety and efficacy with colistin.
Results from the study showed that sulbactam-durlobactam was associated with a 28-day all-cause mortality rate of 19% vs. 32.3% for colistin. It was the top story in infectious disease last week.
Another top story was about the FDA authorization of a second bivalent COVID-19 booster for adults aged 65 years or older and most immunocompromised patients.
Read these and more top stories in infectious disease below:
FDA committee unanimously recommends pneumonia antibiotic for adults
The FDA’s Antimicrobial Drugs Advisory Committee voted unanimously in favor of approving sulbactam-durlobactam for adults with hospital-acquired and ventilator-associated bacterial pneumonia, Innoviva announced. Read more.
FDA OKs second bivalent COVID-19 booster for older adults
The FDA authorized a second bivalent COVID-19 vaccine booster shot for adults aged 65 years or older and most immunocompromised patients, among other changes the agency said will simplify the U.S. vaccine schedule. Read more.
$1.1B program will keep COVID-19 vaccines, treatments free for uninsured in US
HHS announced a $1.1 billion program to keep COVID-19 vaccines and treatments free for uninsured people once the public health and national emergencies end next month in the United States. Read more.
Disturbed sleep associated with symptoms of long COVID, including dyspnea
Sleep disturbance was common among patients hospitalized for COVID-19 and was associated with symptoms of long COVID, including breathlessness and reduced lung function, a study found. Read more.
ID fellowship websites lack diverse, inclusive language
A review of U.S. infectious disease fellowship programs showed that most have room to improve their websites to better display a commitment to diversity, equity and inclusion, which could help recruit more diverse physicians. Read more.